AU2019393347A1 - Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome - Google Patents
Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome Download PDFInfo
- Publication number
- AU2019393347A1 AU2019393347A1 AU2019393347A AU2019393347A AU2019393347A1 AU 2019393347 A1 AU2019393347 A1 AU 2019393347A1 AU 2019393347 A AU2019393347 A AU 2019393347A AU 2019393347 A AU2019393347 A AU 2019393347A AU 2019393347 A1 AU2019393347 A1 AU 2019393347A1
- Authority
- AU
- Australia
- Prior art keywords
- formulation
- pentylphenyl
- acetate
- improving
- histology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775849P | 2018-12-05 | 2018-12-05 | |
| US62/775,849 | 2018-12-05 | ||
| PCT/CA2019/051753 WO2020113340A1 (en) | 2018-12-05 | 2019-12-05 | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019393347A1 true AU2019393347A1 (en) | 2021-07-22 |
Family
ID=70973699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019393347A Abandoned AU2019393347A1 (en) | 2018-12-05 | 2019-12-05 | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220016060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890717A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022510436A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019393347A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121830A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020113340A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2427416B1 (en) * | 2009-05-04 | 2016-03-09 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical uses thereof |
| BRPI1015118A2 (pt) * | 2009-05-04 | 2016-04-12 | Prometic Biosciences Inc | sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos |
| CN105997967B (zh) * | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
-
2019
- 2019-12-05 EP EP19893051.3A patent/EP3890717A4/en not_active Withdrawn
- 2019-12-05 CA CA3121830A patent/CA3121830A1/en active Pending
- 2019-12-05 WO PCT/CA2019/051753 patent/WO2020113340A1/en not_active Ceased
- 2019-12-05 AU AU2019393347A patent/AU2019393347A1/en not_active Abandoned
- 2019-12-05 JP JP2021531937A patent/JP2022510436A/ja active Pending
- 2019-12-05 US US17/311,616 patent/US20220016060A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220016060A1 (en) | 2022-01-20 |
| CA3121830A1 (en) | 2020-06-11 |
| JP2022510436A (ja) | 2022-01-26 |
| EP3890717A4 (en) | 2022-08-24 |
| WO2020113340A1 (en) | 2020-06-11 |
| EP3890717A1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baker et al. | Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization | |
| AU2020233626B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| JP6105546B2 (ja) | ピラゾール誘導体及びその医薬用途 | |
| Buyse et al. | Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance | |
| JP7494277B2 (ja) | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 | |
| JP6561136B2 (ja) | 勃起機能不全を治療又は改善するための方法及びsglt2阻害薬を含む医薬組成物 | |
| US20190350894A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| TWI900606B (zh) | 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合 | |
| BRPI1008560B1 (pt) | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos | |
| JP2018530592A (ja) | 代謝性ミオパチーの治療に使用するためのsglt−2阻害剤 | |
| KR20250140619A (ko) | 고단백뇨 만성 신장 질환의 치료를 위한 지보텐탄과 다파글리플로진의 조합 | |
| US20220016060A1 (en) | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome | |
| KR102512518B1 (ko) | 페마피브레이트를 함유하는 의약 | |
| US20170281803A1 (en) | Renal imaging agent | |
| JP5634985B2 (ja) | インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物 | |
| CA3034956C (en) | TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE | |
| HK40051086A (en) | Methods of treating heart failure with reduced ejection fraction with dapagliflozin | |
| HK40046452A (en) | Use of treating heart failure with reduced ejection fraction with dapagliflozin | |
| CN112336713A (zh) | 利用达格列净治疗射血分数降低的心力衰竭的方法 | |
| Allam et al. | A 77-Year-Old Female With Worsening Shortness of Breath and Leg Swelling | |
| CN120284970A (zh) | Cb-839在制备治疗糖尿病肾脏病药物中的应用 | |
| US9517217B2 (en) | Immune cell activation inhibitor and use thereof | |
| HK40046452B (en) | Use of treating heart failure with reduced ejection fraction with dapagliflozin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |